Beactica Closes Financing Round

Beactica, an Uppsala, Sweden-based a specialist drug discovery company, closed a financing round of undisclosed amount.

The round was led by Almi Invest with participation from Unionen, Uppsala University Holding as well as private investors.

The company intends to use the funds to progress the development of ongoing discovery-stage programs in the area of cancer.

Founded in 2006 and led by Dr Per Källblad, Beactica is developing novel compounds for the epigenetic regulation of various cancer forms through the selective and reversible inhibition of lysine-specific histone demethylases.



Join the discussion